Healthcare: Are These Two Biotech Stocks Too Risky To Buy?​ *** INDUSTRY FOCUS ***

[youtube XsKO8DJuEwc]

MannKind and Orexigen: two companies with big promise, but can they deliver on profit? Healthcare analyst Michael Douglass and healthcare contributor Todd Campbell discuss the risks facing these biotech stocks.

Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete… Now an industry 99% of us use daily is set to implode… And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.

————————————————————————
Subscribe to The Motley Fool’s YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts

Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool

The Motley Fool is a multimedia financial-services company that provides financial solutions for investors through various stock, investing, and personal finance products. Videos provided by and © The Motley Fool.